DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Oxymorphone Hydrochloride is a drug marketed by Actavis Elizabeth, Hikma, Impax Labs, Par Pharm, Specgx Llc, Sun Pharm Inds Ltd, Ascent Pharms Inc, Aurolife Pharma Llc, Avanthi Inc, Epic Pharma Llc, and Teva. and is included in thirteen NDAs.
The generic ingredient in OXYMORPHONE HYDROCHLORIDE is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
A generic version of OXYMORPHONE HYDROCHLORIDE was approved as oxymorphone hydrochloride by IMPAX LABS on June 14th, 2010.
Summary for OXYMORPHONE HYDROCHLORIDE
|Suppliers / Packagers:||8|
|Bulk Api Vendors:||4|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for OXYMORPHONE HYDROCHLORIDE|
|DailyMed Link:||OXYMORPHONE HYDROCHLORIDE at DailyMed|
Recent Clinical Trials for OXYMORPHONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Early Phase 1|
|M.D. Anderson Cancer Center||Early Phase 1|
|Mahidol University||Phase 4|